C-C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice

Background and aims: The global prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing. Chemolcines and their receptors have potential as therapeutic targets of NAFLD. We investigated the role of C-C chemokine ligand 3 (CCL3) in the development of murine and human NAFLD. Methods: CCL3-knockout mice (CCL3(-/-)) and littermate CCL3 wild-type control mice (WT) were fed a high-cholesterol and high-fat (CL) diet for 16 weeks to induce NAFLD. We investigated the impact of CCL3 gene deletion in bone marrow cells and leptin-deficient ob/ob mice on CL diet-induced steatohepatitis. We assayed the serum CCL3 levels in 36 patients with biopsy-proven NAFLD and nine healthy control subjects. Results: Compared with normal chow (NC), the CL diet induced steatohepatitis and hepatic fibrosis and elevated the plasma CCL3 level. In the liver, CCL3 protein colocalized with F4/80(+) macrophages, especially CD11c(+ )M1-like macrophages, rather than other cell types. CCL3(-/-) attenuated CL diet-induced steatohepatitis and fibrosis associated with M2-dominant liver macrophages compared with the WT. The reconstitution of bone marrow (BM) cells from CCL3(-/-) attenuated steatohepatitis in WT mice fed a CL diet. Furthermore, crossing CCL3(-/- )onto the oblob background prevented CL diet-induced NAFLD in ob/ob mice, which was associated with a lesser inflammatory phenotype of liver macrophages. Also, the serum and hepatic levels of CCL3 were significantly increased in patients with non-alcoholic steatohepatitis (NASH) compared to those with simple fatty liver (NAFL) and healthy subjects. Conclusion: Our data indicate that CCL3 facilitates macrophage infiltration into the liver and M1 polarization in the progression of steatohepatitis and highlight the need for further studies to determine the effect of CCL3-CCR1 and -CCR5 signaling blockade on the treatment of NAFLD. (C) 2021 Elsevier Inc. All rights reserved.